Coherus Biosciences Inc. (CHRS) 30.02 $CHRS Coherus

New Post Public Reply Private Reply Replies (0) Message Board

Mar 30, 2015 at 5:34 PM

Coherus Biosciences Inc. (CHRS) 30.02 $CHRS

Coherus initiates equity offering
Seeking Alpha - at Seeking Alpha - 1 hr 12 mins ago

CHRS: 30.02 (+1.61)

Coherus Announces Proposed Public Offering of Common Stock
GlobeNewswire - 1 hr 33 mins ago
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of common stock at the public offering price, less the underwriting discount. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
CHRS: 30.02 (+1.61)

Coherus Biosciences (CHRS) Jumps: Stock Moves Up 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:51AM CDT
Coherus Biosciences, Inc. (CHRS) was a big mover last session, as the company saw its shares rise over 6% on the day.
AFFX: 12.86 (+0.15), CHRS: 30.02 (+1.61)

Biosimilar firms move up
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 12:20PM CDT

EPRS: 8.69 (-0.34), PFNX: 16.62 (+0.10), CHRS: 30.02 (+1.61)

Coherus BioSciences up 21% premarket after earnings release
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 7:29AM CDT

CHRS: 30.02 (+1.61)

Coherus BioSciences ups revenues 442% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 6:28AM CDT

CHRS: 30.02 (+1.61)

This Market Could Grow 6250% in 10 Years
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Mar 23, 4:44PM CDT
Big Pharma just looked into its future... and saw a whole new era dawning. Last year, 32 large-molecule drugs, called biologics, with combined sales of $51 billion, lost patent protection. This year, another $28 billion worth will join them. ...
JNJ: 101.55 (+1.21), BAX: 68.76 (+0.21), C: 51.64 (+0.64), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), ABBV: 58.24 (+0.59), HSP: 87.72 (-0.16), NVS: 101.31 (+0.91), CHRS: 30.02 (+1.61)

Coherus BioSciences reports Q4 results
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:14PM CDT

CHRS: 30.02 (+1.61)

Coherus BioSciences Reports Fourth Quarter and Year End 2014 Financial and Operating Results
GlobeNewswire - Mon Mar 23, 3:00PM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today reported financial results and reviewed corporate events for the quarter and fiscal year ended December 31, 2014.
CHRS: 30.02 (+1.61)

Next Week In Biotech: Pediatric Safety Ad Comm, BIO Asia, Sinovac Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
FLXN: 23.27 (+0.89), MDT: 78.42 (+1.04), RARE: 60.95 (+4.39), PFE: 35.00 (+0.47), SUPN: 11.76 (-0.02), NRX: 8.02 (-0.08), LLY: 73.87 (+0.29), GSK: 47.20 (+0.18), SVA: 4.95 (-0.03), BLRX: 2.16 (+0.01), AMPH: 14.96 (-0.47), CHRS: 30.02 (+1.61), JNJ: 101.55 (+1.21), GNVC: 2.94 (-0.16), CYCC: 0.92 (+0.02), AZN: 69.94 (-0.13), DPRX: 14.12 (-0.04), TEVA: 62.52 (+0.54), NBY: 0.71 (+0.04)

Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
GlobeNewswire - Tue Mar 17, 8:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a leading pure-play, global biosimilars company with late-stage clinical products, today announced that it has finalized the Biologics License Application (BLA) enabling clinical program for CHS-1701, a pegfilgrastim biosimilar candidate, and initiated a pivotal pharmacokinetics and pharmacodynamics (PK/PD) study pursuant to feedback received from the U.S. Food and Drug Administration (FDA) on the CHS-1701 development plan. An additional immunogenicity study is planned in healthy volunteers pursuant to this BLA and is projected to be concluded in 2015 to support submission of the 351(k) (biosimilar) license application for CHS-1701 in Q4 2015 or Q1 2016.
CHRS: 30.02 (+1.61)

Coherus BioSciences to Report Fourth Quarter and Year End 2014 Financial Results on March 23
GlobeNewswire - Mon Mar 16, 8:00AM CDT
Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, March 23, 2015 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and year end 2014 financial results and product updates. Participating on the call will be Denny Lanfear, President and Chief Executive Officer, Barbara Finck, M.D., Chief Medical Officer, and Jean-Frederic Viret, Ph.D., Chief Financial Officer. Prepared remarks will be followed by a question and answer session.
CHRS: 30.02 (+1.61)

FDA clears first biosimilar
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 8:12AM CST

ESPR: 92.04 (+1.39), AMGN: 164.30 (+1.71), PFNX: 16.62 (+0.10), HSP: 87.72 (-0.16), CHRS: 30.02 (+1.61), NVS: 101.31 (+0.91)

Market Is Looking For Positive News - Cramer's Mad Money (3/4/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 05, 6:45AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday, March 4. The market closed lower on Wednesday, but Cramer still thinks the market and stocks will go higher on any positive news. Citing Wayfair's (NYSE: W )...
HYH: 48.65 (+0.68), RH: 99.07 (+2.15), GPRO: 43.58 (+0.88), BIIB: 431.62 (+1.75), BMRN: 129.13 (+0.35), PCYC: 256.43 (-0.12), KMB: 107.74 (+1.37), LLTC: 47.59 (+0.91), BMY: 65.76 (+0.50), ALKS: 62.52 (-0.81), CHRS: 30.02 (+1.61), CELG: 120.02 (+1.34), W: 33.46 (+1.13), ISIS: 64.81 (+1.44), GILD: 100.69 (-0.31), LH: 127.28 (+0.13), MCD: 97.88 (+0.92), REGN: 459.78 (+5.28), BABA: 83.90 (-0.68)

Coherus BioSciences: A Sharp Increase, A Sharp Drop, Plus Collateral News Creates A Buying Opportunity
Regarded Solutions - at Seeking Alpha - Sat Feb 14, 8:50AM CST

JNJ: 101.55 (+1.21), BAX: 68.76 (+0.21), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), HSP: 87.72 (-0.16), CHRS: 30.02 (+1.61)

Biosimilar firms up on Remicade patent rejection
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 11:56AM CST

JNJ: 101.55 (+1.21), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), EPRS: 8.69 (-0.34), PFNX: 16.62 (+0.10), HSP: 87.72 (-0.16), NVS: 101.31 (+0.91), CHRS: 30.02 (+1.61)

Coherus Biosciences (CHRS) Jumps: Stock Moves Up 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 7:51AM CST
Coherus Biosciences, Inc. (CHRS) was a big mover last session, as the company saw its shares rise almost 13% on the day.
AFFX: 12.86 (+0.15), CHRS: 30.02 (+1.61)

Money flowing into small biosimilar firms after Hospira takeout
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 2:51PM CST

PFE: 35.00 (+0.47), EPRS: 8.69 (-0.34), HSP: 87.72 (-0.16), CHRS: 30.02 (+1.61)

Coherus BioSciences to Present at Leerink Healthcare Conference on February 11
GlobeNewswire - Wed Feb 04, 3:07PM CST
Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it will participate in a fireside chat at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11 at 1:50 pm ET in New York City.
CHRS: 30.02 (+1.61)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Gourmia Introduces Ceramic-Coated Air Fryer at Costco

A New Era for Home Cooking with Gourmia Stepping into the kitchen appliances arena with a dash of innovation, Gourmia has launched its first ceramic-coated air fryer, and it’s weaving its way exclusively onto the shelves of Costco. Now, it’s not just about frying anymore; it’s about adding style, efficiency, and a touch of healthy living to your countertop. But much...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...

Cogent Communications' Q3 2026 Earnings Call Details

Cue the Countdown: Cogent’s Earnings Call Looms Another quarter rolls by, and with it comes Cogent Communications' chance to strut—or stumble—before the crowd. Their third-quarter earnings call on November 5, 2026, is like the opening bell for a stock that's zipped through more ups and downs than a tired bullfighter's routine. What the call reveals on that crisp...

A1 Refrigeration Keeps East Texas Homes Comfortable Year-Round

Homeowners in East Texas would agree: the last thing you want is your HVAC system throwing a tantrum when you're in the thick of a scorching summer or a biting winter. That's where A1 Refrigeration & Air Conditioning steps in, making sure folks in Jasper, Brookeland, and Kirbyville aren't left sweating bullets or shivering in their boots. Preventive Maintenance: A...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...